Gastroenterology
Latest news
363 articles · 20 / page
Taipei Global Consensus II (2025): A Practical Guide to Helicobacter pylori Screening and Eradication for Gastric Cancer Prevention
An evidence-based synthesis of the 2025 Taipei Global Consensus II: 28 statements guiding H. pylori screening, eradication, surveillance and stewardship to reduce gastric cancer at individual and population levels.
Endoscopic Ultrasound–Guided Gastroenterostomy Outperforms Surgical Gastrojejunostomy for Malignant Gastric Outlet Obstruction: randomized trial shows faster recovery, shorter stay and lower costs
A multicentre randomized trial found EUS-guided gastroenterostomy (EUS-GE) superior to surgical gastrojejunostomy (SGJ) for malignant gastric outlet obstruction—improving oral intake, shortening hospital stay, enhancing quality of life and
ENDURO trial: EUS‑guided gastroenterostomy shortens time to oral intake and matches surgery for palliation of malignant gastric outlet obstruction
A randomized trial (ENDURO) found endoscopic ultrasound‑guided gastroenterostomy (EUS‑GE) enabled earlier resumption of solid food and was non‑inferior to surgical gastrojejunostomy for recurrent obstruction, supporting EUS‑GE as preferred
EUS-Guided Gastroenterostomy Beats Surgical Gastrojejunostomy for Malignant Gastric Outlet Obstruction: Randomised Trial Shows Faster Diet, Shorter Stay and Lower Costs
A multicentre randomized trial (NCT05548114) found endoscopic ultrasound‑guided gastroenterostomy (EUS‑GE) superior to surgical gastrojejunostomy (SGJ) for malignant gastric outlet obstruction, with faster return to solid diet, shorter hosp
CTNNA1 Truncating Variants Define a Moderate-Penetrance Hereditary Diffuse Gastric Cancer Spectrum — Implications for Testing, Surveillance and Risk Reduction
Large clinical and functional study shows CTNNA1-truncating variants cause loss of αE-catenin via nonsense-mediated decay, confer substantially elevated risks of diffuse gastric cancer and lobular breast cancer versus general population but
Microbiota, 3‑Hydroxyanthranilic Acid and Dopaminergic Signalling: A New Pathway Linking Obesity to Attention Deficits
A multi-cohort human study with mouse and Drosophila validation implicates gut microbes and the tryptophan metabolite 3‑hydroxyanthranilic acid in modulating attention in obesity, suggesting microbiota-directed interventions could improve c
Location Alone Shouldn’t Drive ESD: French Registry Finds Similar Submucosal Cancer Rates in Large Rectal and Colonic Non‑Pedunculated Polyps
A multicentre French ESD registry found that, after adjusting for size and morphology, large non‑pedunculated rectal polyps do not have higher rates of submucosal invasive cancer than equivalent colonic lesions; technical outcomes of ESD we
Lean MASLD Is Not Benign: Higher Liver Events and Mortality in Normal-BMI Patients Across Three Large Cohorts
A pooled analysis of three population cohorts shows lean MASLD carries higher risks of liver-related events and all-cause and liver-related mortality despite lower cardiovascular event risk compared with non-lean MASLD.
PDE5A-Positive Cancer-Associated Fibroblasts Drive Immune Exclusion in Gastric Cancer — Therapeutic Rationale for Combining PDE5 Inhibition with LAG3 Blockade
Single‑cell and spatial profiling identify a PDE5A+ CAF subset that remodels stroma, activates PI3K/AKT/mTOR–CXCL12 signaling, and recruits exhausted LAG3+ CD8 T cells, promoting immune exclusion in gastric cancer. Vardenafil plus LAG3 bloc
GWAS of Idiopathic Achalasia Reveals a Strong HLA Class II–Mediated Immune Aetiology and T-Cell Involvement
A first large GWAS in 4,602 idiopathic achalasia patients implicates class II HLA variation, PTPN22, TNFSF loci and a memory CD8+ T-cell subtype in disease pathogenesis, supporting an immune-mediated aetiology and offering routes for mechan
HBsAg <100 IU/mL Identifies Inactive Chronic HBV Patients with HCC Risk Below Surveillance Threshold
A large Asian cohort study shows serum HBsAg
Peginterferon Add‑On to siRNA JNJ‑73763989 Yields Deep HBsAg Declines but Not Durable Off‑Therapy Cure in HBeAg‑Positive CHB: Phase 2 REEF‑IT Results
In the phase 2 REEF‑IT trial, pegylated interferon‑α2a added to siRNA JNJ‑73763989 produced large HBsAg reductions and transient seroclearance in some untreated HBeAg‑positive patients, but no participant reached the prespecified sustained
Not All ‘Indeterminate’ HBV Is Equal: Specific Indeterminate Types Carry Markedly Higher Long‑Term HCC Risk
A multinational cohort study of 1,986 patients with indeterminate chronic hepatitis B (CHB) shows large differences in long‑term hepatocellular carcinoma (HCC) risk by baseline indeterminate subtype and by phase transition, identifying subg
Seladelpar Significantly Reduces Itch and Sleep Disturbance in PBC: Pooled Phase 3 Evidence and Clinical Implications
Pooled analysis of the ENHANCE and RESPONSE phase 3 trials shows seladelpar 10 mg reduces pruritus and sleep disturbance in patients with primary biliary cholangitis (PBC) and moderate-to-severe baseline itch versus placebo over 6 months, w
Immune-related adverse events strongly predict early graft rejection after liver transplant in HCC patients treated with checkpoint inhibitors
A multicentre retrospective cohort found that pretransplant immune-related adverse events (irAEs) markedly increase the risk of early liver allograft rejection after liver transplantation for hepatocellular carcinoma (HCC). IrAEs, short ICI
Understanding Nonceliac Gluten/Wheat Sensitivity: A Global Perspective on a Common But Complex Condition
Nonceliac gluten/wheat sensitivity affects about 1 in 10 people worldwide, with strong links to female sex, psychological distress, and irritable bowel syndrome. This article explores its prevalence, symptoms, challenges in diagnosis, and i
FDA Approves Linzess for Pediatric IBS with Constipation: A New Hope for Children
The FDA has approved linaclotide (Linzess) for treating irritable bowel syndrome with constipation (IBS-C) in children 7 and older, marking the first official treatment option for pediatric IBS-C.
Therapeutic Plasma Exchange May Improve Transplant-Free Survival in Severe Amatoxin-Associated Acute Liver Failure
A multinational retrospective cohort found adjunctive plasma exchange was associated with higher 28‑day transplant-free survival in amatoxin-related ALF patients with grade ≥2 hepatic encephalopathy.
Predicting Early Acute Kidney Injury After Liver Transplantation: A Clinically Useful 48‑Hour Risk Model
A single-center study developed and internally validated a 48‑hour post‑liver transplant AKI risk model using five readily available preoperative and intraoperative variables (HE, alcohol cirrhosis, ALBI ≥ −1.78, operation time ≥560 min, an
Exceptional Efficacy of Olverembatinib in a Subtype of Gastrointestinal Stromal Tumors with Marked Improvement in Progression-Free Survival
Olverembatinib showed outstanding efficacy in treating succinate dehydrogenase (SDH)-deficient gastrointestinal stromal tumors (GIST), significantly extending median progression-free survival to 25.7 months compared to traditional therapies
Browse by specialty
Open language-specific specialty feeds and department pages.